Drake Compared to Other Public GLP-1 Figures

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Drake Compared to Other Public GLP-1 Figures

At a glance

  • Drug confirmed: Semaglutide (Ozempic), a GLP-1 receptor agonist
  • Disclosure method: Social media posts, 2023 (confirmed)
  • Visible change noted by media: Body composition shift documented in mainstream coverage, 2022 to 2024
  • Comparison group: Publicly confirmed and publicly speculated GLP-1 users across celebrity cohort
  • Clinical significance: One of the first male celebrities to normalize GLP-1 use openly

Drake's Public Record, Precisely

In 2023, Drake referenced Ozempic use in social media posts, making the disclosure casual rather than confessional. That tone matters clinically and culturally. He did not frame the drug as a last resort or a medical necessity. He mentioned it the way someone might mention a supplement or a fitness protocol. That directness is rare. Most celebrity GLP-1 disclosures, when they happen at all, arrive under pressure from tabloid scrutiny rather than as voluntary statements.

Mainstream outlets including People magazine and E! News covered the disclosure in 2023 and documented a visible body composition change across public appearances from roughly 2022 through 2024. The HealthRX Medical Team notes that attributing any physical change solely to one drug is not clinically sound without direct medical history, but the timeline aligns with Drake's own confirmed use.

How Drake's Disclosure Compares to Other Public Figures

A small but growing number of public figures have addressed GLP-1 use directly. The table below maps confirmed versus speculated status as of mid-2024.

| Public Figure | Drug | Status | Disclosure Method | |---|---|---|---| | Drake | Ozempic (semaglutide) | Confirmed | Social media, 2023 | | Oprah Winfrey | GLP-1 class (unnamed) | Confirmed | People magazine interview, 2024 | | Elon Musk | Wegovy (semaglutide) | Confirmed | Twitter/X post, 2022 | | Sharon Osbourne | Ozempic | Confirmed | The Talk, 2023 | | Chelsea Handler | Ozempic | Confirmed | Interview via Today, 2023 | | Rybelsus/GLP-1 use (multiple unnamed industry figures) | Various | Speculated | Not publicly confirmed |

Several other celebrities, including various actors and musicians whose names have circulated in tabloid coverage, have not publicly confirmed GLP-1 use. The HealthRX Medical Team treats those cases as speculated only and does not name individuals without confirmation.

What separates Drake's disclosure from most others is gender and timing. Oprah Winfrey's confirmation in early 2024 received enormous coverage, but her disclosure came after Drake's and after a longer period of public speculation. Elon Musk's 2022 tweet predates Drake's post, but Musk referenced Wegovy specifically as an add-on to fasting, framing it differently. Drake's statement arrived in the window when male GLP-1 use was rarely discussed openly, giving it outsized cultural weight.

What GLP-1 Receptor Agonists Actually Do

Semaglutide, the active molecule in both Ozempic and Wegovy, is a glucagon-like peptide-1 receptor agonist. It mimics the endogenous GLP-1 hormone released from intestinal L-cells after eating. The receptor binding produces three clinically meaningful effects: enhanced glucose-dependent insulin secretion, suppressed glucagon release, and delayed gastric emptying. The last effect is largely responsible for the satiety signal that reduces caloric intake. A 2021 phase 3 trial published in the New England Journal of Medicine demonstrated a mean body weight reduction of 14.9 percent with once-weekly 2.4 mg semaglutide versus 2.4 percent with placebo over 68 weeks in adults without diabetes.

Ozempic is FDA-approved for type 2 diabetes management at doses up to 2 mg weekly. Wegovy carries FDA approval specifically for chronic weight management at 2.4 mg weekly. The FDA prescribing information for semaglutide injection details the dose-escalation schedule: 0.25 mg weekly for four weeks, stepping up at four-week intervals to reduce gastrointestinal side effects. When Ozempic is used for weight management without a diabetes diagnosis, it is prescribed off-label at the diabetes-approved doses, which is legal but outside the labeled indication.

Side Effect Profile and Contraindications

The most commonly reported adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In the STEP 1 trial cited above, nausea occurred in 44 percent of the semaglutide group versus 16 percent of the placebo group, though most cases were transient and resolved with dose escalation. The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent studies. The clinical relevance in humans remains under investigation, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Pancreatitis is a labeled risk. Gallbladder disease, including cholelithiasis, is more common with GLP-1 therapy than with placebo. A 2022 analysis in JAMA Internal Medicine found elevated gallbladder-related event rates across GLP-1 receptor agonist trials. Prescribers are expected to evaluate these risks individually before initiating therapy.

The HealthRX Medical Team notes that for otherwise healthy individuals using GLP-1 agents off-label for body composition goals rather than metabolic disease, the risk-benefit calculation differs meaningfully from the diabetic patient population where the drug's cardiovascular outcome data, including the SUSTAIN-6 trial, establishes clear benefit.

What the Pattern of Celebrity Disclosure Teaches Clinicians

When multiple high-profile individuals confirm use of a medication in a short window, prescribing behavior in the general population tends to follow. The American Diabetes Association's 2024 Standards of Care already reflect GLP-1 agents as preferred agents for patients with obesity and cardiovascular risk, regardless of diabetes status. The celebrity disclosure pattern has arguably accelerated patient interest ahead of primary care provider readiness.

Drake's role in this pattern is specific. Male celebrities rarely discuss weight management pharmacology at all, let alone casually. His disclosure helped shift GLP-1 therapy away from a perception as primarily a tool for women or for people with severe obesity, toward a general body-composition intervention that men with access to concierge medicine or informed prescribers might consider. That shift has real clinical consequences. It increases the probability that men present to their physicians asking about GLP-1 options, which creates an opportunity for proper screening, including cardiovascular history, thyroid history, and metabolic panels, before prescribing begins.

The HealthRX Medical Team considers the normalization effect a net positive if it drives patients toward supervised medical care rather than gray-market access. Compounded semaglutide, which proliferated during the FDA-documented shortage period, raises separate safety concerns that supervised prescribing avoids.

Clinical Perspective: Male Body Composition and GLP-1

Men and women differ in fat distribution, muscle mass proportion, and baseline metabolic rate, which affects how GLP-1-driven caloric restriction manifests physically. Men generally carry more lean mass, and there is some clinical interest in whether GLP-1-induced weight loss disproportionately reduces lean tissue. A 2023 study in Obesity found that semaglutide-associated weight loss included both fat mass and lean mass reduction, with the lean mass component raising questions about concurrent resistance training and protein intake optimization.

The HealthRX Medical Team recommends that any patient, celebrity or otherwise, initiating GLP-1 therapy maintain or increase resistance training and consume adequate dietary protein (at minimum 1.2 g per kg body weight daily) to preserve lean mass during the caloric deficit the drug produces. This is not specific advice for Drake, whose training and nutrition regimen is not publicly documented in medical detail. It is general clinical guidance applicable to the population of otherwise healthy men using GLP-1 agents off-label.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  • Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
  • FDA Prescribing Information, Wegovy (semaglutide) injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  • Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists. JAMA. 2023. https://jamanetwork.com/journals/jama/fullarticle/2810542
  • Gallbladder events and GLP-1 receptor agonists. JAMA Internal Medicine. 2022. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2798896
  • American Diabetes Association. Standards of Care in Diabetes 2024. https://diabetesjournals.org/care/article/47/Supplement_1/S1/153947/Introduction-Standards-of-Care-in-Diabetes-2024
  • FDA Drug Shortage Notice: Ozempic. https://www.fda.gov/drugs/drug-shortages/ozempic-semaglutide-injection-shortage
  • Semaglutide and lean mass. Obesity. 2023. https://pubmed.ncbi.nlm.nih.gov/37073530/
  • Oprah Winfrey confirms weight loss medication use. People Magazine. 2024. https://people.com/oprah-winfrey-uses-weight-loss-medication-8585796